Early Phase 3 Results Highlight Potential of TLX591-Tx in Prostate Cancer Treatment
Telix Pharmaceuticals Limited (ASX: TLX) operates as an international biotechnology company dedicated to creating radiopharmaceutical treatments and diagnostic imaging solutions aimed at improving the detection and management of cancer.
The company recently reported early results from Part 1 of its global Phase 3 ProstACT study evaluating TLX591-Tx, a targeted radiopharmaceutical therapy for metastatic castration-resistant prostate cancer. The lead-in phase enrolled 36 patients who received two doses of the therapy alongside standard treatments such as abiraterone, enzalutamide, or docetaxel. The study met its primary objectives by confirming safety, pharmacokinetics, and radiation distribution across treatment cohorts.
Findings showed no new safety concerns, while most non-hematologic side effects were mild, including fatigue, nausea, and dry mouth. Blood-related effects such as thrombocytopenia and neutropenia were consistent with expectations for this therapy class and were temporary and manageable. Importantly, radiation exposure to critical organs such as the kidneys and salivary glands remained low, supporting the treatment’s tolerability profile.
The therapy also demonstrated sustained tumor targeting, with imaging showing radiation activity retained in tumors for up to 15 days. These results support progression to the larger randomized Phase 3 expansion stage of the study.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Early Phase 3 Results Highlight Potential of TLX591-Tx in Prostate Cancer Treatment
Telix Pharmaceuticals Limited (ASX: TLX) operates as an international biotechnology company dedicated to creating radiopharmaceutical treatments and diagnostic imaging solutions aimed at improving the detection and management of cancer.
The company recently reported early results from Part 1 of its global Phase 3 ProstACT study evaluating TLX591-Tx, a targeted radiopharmaceutical therapy for metastatic castration-resistant prostate cancer. The lead-in phase enrolled 36 patients who received two doses of the therapy alongside standard treatments such as abiraterone, enzalutamide, or docetaxel. The study met its primary objectives by confirming safety, pharmacokinetics, and radiation distribution across treatment cohorts.
Findings showed no new safety concerns, while most non-hematologic side effects were mild, including fatigue, nausea, and dry mouth. Blood-related effects such as thrombocytopenia and neutropenia were consistent with expectations for this therapy class and were temporary and manageable. Importantly, radiation exposure to critical organs such as the kidneys and salivary glands remained low, supporting the treatment’s tolerability profile.
The therapy also demonstrated sustained tumor targeting, with imaging showing radiation activity retained in tumors for up to 15 days. These results support progression to the larger randomized Phase 3 expansion stage of the study.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au